SANOFISanofi India Ltd.

₹4681.1-0.38%

Market Cap

₹10,824.28 Cr

Stock P/E

26.19

ROCE

46.16%

ROE

36.10%

Book Value

₹343.51

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
One Diabetes Business Unit consolidation expands reach and alignment of anti-diabetes products.
•
Diabetes disease awareness campaign reached over 200 million people in 2023.

NEGATIVES

•
Lantus price reductions under NLEM weighed on the diabetes portfolio, offset only by other portfolios.
•
Management cautions on future visibility: no earnings guidance and limited disclosure on product-level details.

Peers Summary

Sector Leader

Sanofi India Ltd. demonstrates solid profitability metrics with a high ROE and low debt, however, it struggles with revenue growth compared to its peers. Meanwhile, companies like Cipla and Mankind Pharma stand out with their strong growth trajectories and attractive valuations, positioning them well in the sector.

Key Points

• Sanofi India Ltd. has the highest ROE at 36.10% but shows negative revenue growth YoY.
• Cipla Ltd. and Mankind Pharma Ltd. show strong revenue growth and solid profitability, making them top picks in the sector.
• Sanofi has a low debt-to-equity ratio, indicating financial stability, while some peers carry heavier debt loads.

Top Performers

Cipla Ltd.

Strong growth (YoY revenue growth of 13.28%) coupled with attractive valuation metrics (PE of 23.73).

Mankind Pharma Ltd.

Exceptional revenue growth (18.12% YoY) and strong profitability indicators with a low debt-to-equity ratio.

Explore

Watchlists

Command Palette